Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and in Vitro Efficacy for Rifampicin and SQ641

[Image: see text] Tuberculosis (TB) remains a major global health concern, and new therapies are needed to overcome the problems associated with dosing frequency, patient compliance, and drug resistance. To reduce side effects associated with systemic drug distribution and improve drug concentration...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Addio, Suzanne M., Reddy, Venkata M., Liu, Ying, Sinko, Patrick J., Einck, Leo, Prud’homme, Robert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423248/
https://www.ncbi.nlm.nih.gov/pubmed/25811733
http://dx.doi.org/10.1021/mp5008663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423248/
https://www.ncbi.nlm.nih.gov/pubmed/25811733
http://dx.doi.org/10.1021/mp5008663

Ejemplares similares